Wave Q1 revenue $38.2M; net loss narrows to $26.1M; WVE-007 Phase 2a begins Q2 2026

Wave Life Sciences Ltd.

2026-Q1 EPS reported -$0.13 revenue$38,246,000

Revenue $38.2M (up from $9.2M); net loss $26.1M (vs $46.9M).
Cash $544.6M; runway into Q3 2028, excluding GSK milestones.
FDA accepted Phase 2a multidose portion of WVE-007 (obesity); trial to start Q2 2026.
Phase 1 six-month data: total fat -5.3%, visceral fat -14.3% (p<0.05), muscle +2.4%.
WVE-006 AATD data at ATS May 18 & EASL May 29; accelerated approval feedback mid-2026.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Wave Life Sciences Ltd. reported financial results for quarter ended March 31, 2026.

Period: quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On April 28, 2026, Wave Life Sciences Ltd. (the “Company”) announced its financial results for the quarter ended March 31, 2026.

View on SEC.gov

1436 earnings releases filed in the last 30 days. Browse all earnings releases →

Wave Life Sciences Ltd. filing history →

Source: SEC EDGAR

accession 0001193125-26-183563

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.